Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

NCT06128863 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant
Immunotherapy
Sarcoma,Soft Tissue
Radiation Therapy

Interventions

DRUG: Pembrolizumab, Eftilagimod alfa

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology

Collaborators

[object Object]